Previous study has reported that aberrant DNA methylation was significantly associated with poorer prognosis [14, 25] and more resistant to chemotherapy and BRAF inhibitors in melanoma.[26] The reversible nature of DNA methylation makes it a desirable therapeutic target of combination treatment. The gene discussed is BRAF; the disease is melanoma.